| Primary Identifier | IPR043445 | Type | Family |
| Short Name | TMEPAI/LRAD4 |
| description | This entry includes TMEPAI and LRAD4 (C18ORF1). They contain two PY motifs and one Smad-interacting motif (SIM) domain. They are both known to inhibit transforming growth factor-beta (TGF-beta) signalling via its competition for binding of receptor-regulated Smad with Smad anchor for receptor activation [, ].TMEPAI was originally identified as a highly androgen-induced gene by serial analysis of gene expression in androgen-treated LNCaP prostate cancer (CaP) cells []. It is a type I transmembrane protein that has an N-erminal extracellular and a single transmembrane domains. TMEPAI contains two PY motifs that can be targetedby the WW domain. It is involved in a negative feedback loop to control the duration and intensity of TGF-beta signaling, which regulates growth suppression, apoptosis induction, extracellular matrix production, and differentiation []. It is also involved in androgen receptor signalling, phosphatase and tensin homologue deleted on chromosome 10 signalling, and formation of autophagosomes in addition to degradation of TbetaRI (TGF-beta type I receptor) through lysosomes []. TMEPAI has been linked to cancers [, , ].Low-density lipoprotein receptor class A domain-containing protein 4 (LRAD4) is a negative regulator of TGF-beta signaling. TMEPAI might help LRAD4 to inhibit TGF-beta signaling in a coordinated manner when cells are stimulated with high levels of TGF-beta []. LRAD4 is elevated in hepatic cancers and tumour tissues []. |
